Healthcare / Medical DevicesBSE
$136.00
+3.40 (+2.56%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-25.2M · quality 55.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
56/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$775M
P/E
15.0x
↓EV/EBITDA
0.6x
↓ROE
8.4%
↑Gross Margin
17.7%
↓Debt/Equity
0.13
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+146.7%
FCF CAGR
—
FCF margin
-10.0%
FCF / Net income
-1.19x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $369.8M · net income $31.0M · FCF $-37.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $369.8M | $369.8M | $155.8M | $7.2M | $24.6M |
| Net Income | $31.0M | $31.0M | $13.9M | $-4.8M | $-4.2M |
| EBITDA | $53.7M | $53.7M | $20.8M | $-14.4M | $-8.0M |
| EPS | 5.44 | 5.44 | 2.43 | -1.22 | -1.08 |
| Gross Margin | 17.7% | 17.7% | 15.4% | 31.4% | 29.7% |
| Operating Margin | 9.9% | 9.9% | -0.8% | -223.2% | -39.1% |
| Net Margin | 8.4% | 8.4% | 8.9% | -66.1% | -17.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.13 | 0.13 | 0.11 | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-37.0M | $-37.0M | $26.7M | $-25.2M | $-5.6M |
| Returns | |||||
| ROE | 8.4% | 8.4% | 4.1% | -3.1% | -2.6% |
| Valuation | |||||
| P/E | 14.99 | 14.99 | 26.10 | — | — |
| EV/EBITDA | 0.56 | 0.56 | -1.82 | — | — |
| P/B | 0.21 | 0.21 | 0.11 | 1.18 | 0.98 |
| Growth & Yield | |||||
| Revenue Growth | 137.3% | 137.3% | 2068.1% | -70.8% | — |
| EPS Growth | 123.9% | 123.9% | 299.2% | -13.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
30.4%
EPS terminal req.
$12.07
Spread vs growth
93.4%
5Y implied EPS CAGR
21.8%
EPS terminal req.
$14.60
Spread vs growth
102.0%
10Y implied EPS CAGR
15.8%
EPS terminal req.
$23.52
Spread vs growth
108.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+42.1%
Start / end P/E
39.4x → 25.0x
EPS bridge
2.43 → 5.44
Residual
-45.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.